Technology whitespaces India should focus: a comparative anti-cancer patent rational analysis of Indian and international public funded universities.
The article reported an in-depth comparative technology analysis of 1708 Anti-cancer patents from top 20 international universities and leading 10 Indian public funded organization and research institutes. The study segregated pioneer universities vs. technologies used in the field of Anticancer research at a level of drug discovery, development, diagnosis and treatment, which are illustrated in the form of novel substantive patent landscape maps. The reported competitive intelligent maps identified genetics, composition and synthetic compounds as dominating technologies; followed by natural extracts, combination and drug delivery systems as upcoming technologies. The least number of patents were reported by surgical apparatus, targeted therapy and animal models. In addition, the study analysed the key technologies followed by Indian universities in comparison to the international universities, to identify the overlooked technologies by the Indian public funded institutes. In an ever changing competitive world, it is essential for every university to have their own research plan and thrust areas; but at the same time, it is equally important for any organisation to have an idea of their competitor's research plan as well. So, the article suggested Indian institutes to focus on the latest emerging Anti-cancer technology trends, which are in practice by the international universities. Concurrently, this study may be a landmark indication for Indian public funded universities and institutes, calling for a U-turn from their traditional approaches.
Ajay
A
Dara
Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab 160062, India. abhays@niper.ac.in.
Abhay T
AT
Sangamwar
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D007194:India; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D010330:Patents as Topic; D013673:Technology Assessment, Biomedical / Q000639:trends; D014495:Universities
D000970:Antineoplastic Agents